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Abstract
Background: New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional
vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a
lack of evidence on the effectiveness and safety of Rivaroxaban in Cerebral venous thrombosis (CVT). This study
aims to assess the effectiveness and bleeding risk of Rivaroxaban in comparison with Warfarin for the treatment of
CVT.
Materials and methods: 36 patients with diagnosis of CVT were included. Clinical and background information
was assessed on admission and patients were followed for at least 12 months. Measured outcomes were modified
Rankin Scale (mRS), evidence of recanalization on contrast-enhanced Brain MR venography (MRV) and major or
minor bleeding. Patients were divided into two groups according to the type of oral anticoagulant (Rivaroxaban vs
Warfarin). Groups were compared in terms of final outcomes and side effects.
Result: Overall, 13 (36.11%) patients received Warfarin and 23 (63.89%) received Rivaroxaban. Optimal mRS score
(0–1) was attained in 9 of 10 (90%) of patients treated with Rivaroxaban and 19 of 22 (86.36%) of patients received
Warfarin. MRV showed complete or partial recanalization in 12 of 14 (85.71%) patients treated with Rivaroxaban and
all patients in the Warfarin group. There was no significant difference between the two groups in terms of major
and minor hemorrhage.
Conclusion: Rivaroxaban holds promise for the treatment of CVT.
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Background
Cerebral venous thrombosis (CVT) is a clinical condition in
which the brain’s venous drainage is impaired. This, in turn,
may lead to brain ischemia or hemorrhage [1]. The incidence
of CVT is 2 to 5 cases per million per year in the population
[2] and it accounts for about 0.5% of strokes [3].
Diagnosis of CVT is confirmed via appropriate im-
aging modalities, including Brain CT scan and Magnetic
Resonance Venography (MRV) [4]. Administration of
heparin or Low Molecular Weight Heparin (LMWH)
followed by an anticoagulant is the current approved
management in CVT patients [5]. Warfarin is the most
frequently prescribed medication [4]; However, it has its
own limitations need for continuous monitoring, bleed-
ing risk, and variable bioavailability due to dietary inter-
action [6].
Over the last decades, Novel Oral Anticoagulants
(NOACs) such as Rivaroxaban might offer a convenient
alternative to Warfarin in some thrombotic and
thromboembolic disorders [7, 8] Some evidence shows
that NOACs generally reduce the potential risks of
major and fatal hemorrhages, the major adverse event of
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anticoagulant drugs, compared to vitamin-K antagonists
[9–11]. Some reports have shown that Rivaroxaban has
a therapeutic effect equivalent to Warfarin in deep vein
thrombosis and pulmonary embolism [12, 13]. It has
been recently presumed that it could be possible to use
Rivaroxaban in cases of CVT as well; however, this con-
cept is relatively new with insufficient evidence. Thus, its
utilization in the CVT treatment is still under debate.
Only a few reports have addressed this issue; they show
similar clinical efficacy of factor Xa inhibitors to War-
farin for CVT treatment and reduced risk for complica-
tions [14–16]. Ongoing RCT studies comparing
Rivaroxaban and Warfarin are underway
(NCT03178864, and NCT04569279).
Since Rivaroxaban’s benefits may exceed that of War-
farin due to no need for continuous monitoring and no
dietary interaction, this study is an attempt to address
the question of whether Rivaroxaban can be a viable al-
ternative to warfarin or not.
Materials and methods
In this retrospective study, we included 36 patients ad-
mitted to a central neurology hospital affiliated to Iran
University of Medical Sciences, Tehran, Iran from 2017
to 2020 with cerebral venous/sinus thrombosis. The
diagnosis had been confirmed by filling defects at si-
nuses on post-contrast enhanced Brain MR venography
(MRV) (Fig. 1 a,b). Initial relevant demographic data and
clinical features including predisposing factors, clinical
findings, imaging characteristics, the prescribed anti-
coagulant drug at the time of hospitalization, and dis-
charge were obtained from patients’ documents.
Classification of patients with hemorrhagic brain lesion
were done according to European Cooperative Acute
Stroke Study (ECASS) [17].
During the hospitalization, all patients were treated
with either Heparin or LMWH (Enoxaparin). After the
initial phase, oral anticoagulants started either Warfarin
or Rivaroxaban (as an off-label medication). None of the
clinical symptoms, predisposing factors including hyper-
coagulation state, or imaging findings played a role in
the type of drug (Rivaroxaban or Warfarin) prescribed
by the physicians and the selection was solely made ac-
cording to physician and patients’ preference. The pa-
tients' glomerular filtration rate (GFR) was calculated
based on renal creatinine clearance and Rivaroxaban
dose was adjusted accordingly. The initial dose of Rivar-
oxaban was 20mg in patients with normal renal function
and it was maintained if side effects did not occur. War-
farin was started at 5–10 mg, and further increased
based on serial INR results. Dosage adjustment in pa-
tients was performed according to the European Heart
Rhythm Association (EHRA) protocol in patients with
renal insufficiency. Renal function was monitored
regularly according to the protocol. In patients with
GFR above 60ml/min renal function was assessed every
12 months. In patients with GFR < 60 recheck interval
was calculated by dividing creatinine clearance by 10 (re-
check interval = CrCl/10) [18].
Patients were divided into two groups according to
oral anticoagulant (Warfarin vs. Rivaroxaban). Patients’
follow-up began 12months after the hospitalization
period. They were followed up for treatment assess-
ments and possible side effects through face-to-face
evaluation by a staff neurologist. Follow-ups included
clinical evaluation in terms of modified Rankin Scale
(mRS), and inquiry about the occurrence of any other
events of CVT during therapy. Furthermore, the occur-
rence of any type of bleeding was noted. In cases of
bleeding, the severity and complications were asses-
sed.MRS 0 or 1 were considered as favorable outcome
[15]. 3 patients were missed to follow-up, thereby were
not included in the final analysis. Similarly, the final
contrast-enhanced brain MR venography was assessed
for detecting recanalization. (Fig. 1 c,d) The MRV results
were categorized into two groups of complete and par-
tial recanalization. Subsequently, both groups were com-
pared in terms of the final outcomes and side effects.
This research was conducted according to institutional
and national policies. Consent forms were obtained from
patients prior to using their clinical data. Patient records
were obtained and included anonymously. All stages of
the project were approved by the Research Ethics Com-
mittee (Code: IR.IUMS.REC.1399.436).
The results of quantitative statistics were expressed as
mean and standard deviations, while qualitative data was
presented by their frequency (percent). To assess the re-
lationship between categorical variables, the Fisher exact
or Chi-square test was utilized. Mann–Whitney test was
used to compare quantitative variables between two
groups. Statistically, P-value < 0.05 was considered sig-
nificant. All data were analyzed by SPSS version 26
software.
Results
A total of 36 patients were included, among which 29
were female (80.56%). The mean age was 35.69 ± 10.87.
Three patients were missed to follow-up due to their un-
willingness to participate in the study, thus excluded for
further analysis (Table 1).
After 12 months follow-up, 9 of 10 (90%) of patients
treated with Rivaroxaban and 19 of 22 (86.36%) of
patients treated with Warfarin had a favorable mRS
score (0 or 1). There was no statistically significant
difference between the two groups in terms of the
final mRS score (P-value> 0.05). None of the patients
in either group died during the 12 months. One pa-
tient in the Rivaroxaban group experienced another
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CVT during the treatment period. Also, one patient
in the Warfarin group experienced Deep Vein
Thrombosis (DVT) during the treatment period. Con-
cerning Imaging, MRV showed that recanalization ei-
ther complete or partial, occurred in 12 of 14
(85.71%) of patients treated with Rivaroxaban and
100% of patients treated with Warfarin. The MRV in
all patients of the warfarin group showed recanaliza-
tion and just two patients (14.29%) in the group of
Rivaroxaban had no recanalization. This difference be-
tween the two groups was not statistically significant
(P-value> 0.05) (Table 2).
Three patients treated with Rivaroxaban experienced
minor bleeding and 2 cases experienced the same in
the other group. The difference between the two
groups was not statistically significant (P-value> 0.05).
There was no report of any major bleedings as side
effects of Warfarin or Rivaroxaban. Bleedings were all
cured without further complications after dose
adjustment.
Discussion
This study aimed to compare the benefits and risks of
Rivaroxaban with Warfarin in patients with cerebral ven-
ous thrombosis (CVT).
In this study, anticoagulant therapy was maintained by
either Rivaroxaban, or dose-adjusted Warfarin for 12
months. As stated, none of the clinical symptoms, pre-
disposing factors inducing hypercoagulation state or im-
aging findings played a role in the type of drug
Fig. 1 Contrats-enhanced Magnetic Resonance venography of a patient with Cerebral Venus Thrombosis (CVT). At the time of hospitalization and
at 12-month follow-up. a. At the time of hospitalization, coronal (a) and sagittal (b) contrast-enhanced MR venography showed a filling defect in
the right transverse sinus, compatible with cerebral venous thrombosis. At 12-month follow-up, coronal (c) and sagittal (d) contrast enhanced MR
venography showed recanalization of right transverse sinus
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(Rivaroxaban or Warfarin) prescribed by the physicians,
and the drug option was solely selected based on phys-
ician and patients’ preference. The initial dose of Rivar-
oxaban was 20mg and it was maintained unless bleeding
occuredoccured [19].
Both drugs were rarely associated with major bleeding
events, there have been no new intracranial hemorrhages
nor any expansion of initial hemorrhagic lesions. No sig-
nificant bleeding risk was observed with Rivaroxaban
compared to Warfarin; this result was similar previuos
the studies on Rivaroxaban used for CVT or other
thrombotic diseases such as Deep Vein Thrombosis or
Pulmonary Thromboembolism [15, 16, 20–22].
Patient outcomes were measured by the mRS score
and thrombosis recanalization by MR venography. Des-
pite the small sample size, the groups did not differ sig-
nificantly in terms of final clinical outcome and evidence
of recanalization in MRV. Specifically, 90% of patients
treated with Rivaroxaban had a favorable mRS score of 0
or 1 which seems to be, albeit insignificantly, higher than
Table 1 Demographic and clinical background
Variables All patients (n = 36) Warfarin (n = 13) Rivaroxaban (n = 23) P value
Age 36 34 ± 11.22 36 ± 11.15 0.510






OCP or hormone therapy 7 (19.44%) 3 (23.1%) 4 (17.4%) 0.050
Predisposing genetic hyper coagulopathy 12 (33.33%) 7 (53.8%) 5 (21.7%)
Malignancy 4 (11.11%) 0 4 (17.39%)
Cerebral lesion 0.708
Ischemic 25 (69.4%) 10 (76.9%) 15 (65.2%)
Hemorrhagic 11 (36.6%) 3 (23.1%) 8 (34.8%)
PHI 8 (81.82%) 3 (100%) 6 (75%)
PHII 2 (18.18%) 0 (0%) 2 (25%)
OCP Oral Contraceptive Pill, PH Parenchymal Hemorrhage (European Cooperative Acute Stroke Study classification) Quantitative statistics were shown using Mean
and Standard Deviations, Mean ± (SD)
Table 2 Clinical findings, side effects and treatment outcomes
Clinical findings All patients (36) Warfarin
(13)
Rivaroxaban (23) P value
Duration of hospitalization (days) 16.77 ± 10.69 11.7 ± 7.61 0.133
Loss of consciousness 7 (19.44%) 0.382
Yes 1 (7.7%) 6 (26.1%)
No 12 (92.3%) 17 (73.9%)
Outcomes of treatment
Minor bleeding 5 (15.63%) 2/10 (20%) 3/22 (13.63) 0.708
Major bleeding 0 0 0
mRS 32a 10 22 > 0.999
mRS (0 or 1) 28 (87.5%) 9 (90%) 19 (86.36%)
mRS 2 4 (12.5%) 1 (10%) 3 (13.63%)
MRV (Recanalization) 19a 5 14 > 0.999
Recanalized 17 (93.75%) 5 (100%) 12 (85.71%)
Complete 14 (84.37%) 4 (80%) 10 (83.33%)
Partial 3 (9.38%) 1 (20%) 2 (16.67%)
Not recanalized 2 (6.25%) 0 2 (14.29%)
mRS modified ranking scale, MRV magnetic resonance venography. Quantitative statistics were shown using Mean and Standard Deviations, Mean ± (SD)
a The number of the statistical population in the follow-up (mRS and MRV) was lower than the initial population due to not answering the phone call or
unwillingness to participate in follow-up
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the warfarin group. Only one case in the Rivaroxaban
group experienced new venous/sinus thrombosis. Inquir-
ies revealed that this patient changed the dose of Rivar-
oxaban to 10 mg, and did not continue the advised 20
mg dosage. No death was reported in either group dur-
ing 12months follow-up.
Moreover, 85.7% of patients in the Rivaroxaban group
showed complete recanalization in MRV after 12months
while, recanalization occurred in 100% of the Warfarin
group. This difference was not significant between the two
groups. Previous studies, either case reports or small
population studies on CVT, have shown high efficacy of
factor Xa-inhibitor drugs, especially in the case of Rivarox-
aban. Resulting in high rates of recanalization and optimal
mRS score (0–1) [15, 16, 20, 23].
The present research findings on side effects and clin-
ical outcomes are consistent with those of previous stud-
ies on Rivaroxaban for the treatment of thrombotic
disorders other than CVT (12). An important consider-
ation in comparing different studies are predisposing
factors including sex, age, and history of thrombophilia
or hypercoagulable state. Further, the duration of follow-
up may play a determining role in clinical outcomes. For
example, recanalization rates in our study were superior
to those reported by Geisbusch et al. and Lurkin et al.
[15] and this can be due to our follow-up time, 12
months, which is longer than the mentioned studies (8
and 6months respectively) [15, 24] . Also, Lurkin et al.
[24], used different types of NOAC drugs other than
Rivaroxaban, including Apixaban or Dabigatran.
Limitations
Since the present work is a retrospective study with
small sample size, the findings should be deduced with
caution. Furthermore, prescribing Rivaroxaban or War-
farin according to preference of related physician limits
our study. Future prospective studies with a larger study
group should be performed.
Conclusion
The efficacy of Rivaroxaban in CVT might not be infer-
ior to vitamin K antagonists. The risk of bleeding in pa-
tients treated with Rivaroxaban, as a major concern of
anticoagulant therapy, seems not to be superior to that
of Warfarin.
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